Proceedings · Session S-279 · filed November 19, 2026
AI & Emerging Tech in R&DSession paper
ParkourSC Buys Quartic to Merge Factory and Supply-Chain Data
ParkourSC has acquired Quartic to merge manufacturing and supply-chain AI into one record, reporting 15–20% biologics yield gains and faster cold-chain release decisions.
By Rebecca Stone3 min read658 words
Summary
- ParkourSC, based in San Jose, acquired manufacturing AI firm Quartic; financial terms were not disclosed.
- The companies report 15–20% gains in biologics batch yield from shared multivariate models across clinical and commercial production.
- The combined platform predicts which batches, lots and shipments are at risk across one continuous record.
- CEO Mahesh Veerina states AI only recommends: a qualified person makes every GxP decision with an e-signature and audit trail.
- The platform uses interpretable statistical methods only — no black-box models or LLMs — and attaches confidence intervals to recommendations.

ParkourSC, a San Jose supply-chain analytics vendor, has acquired Quartic, a manufacturing AI firm, to combine batch production data and downstream distribution records on a single platform for regulated life sciences companies. The companies report the merged modeling approach has delivered 15 to 20% gains in biologics batch yield, and ParkourSC claims the deal creates one continuous record that can predict which batches, lots and shipments are at risk.
The commercial logic is straightforward. A drug's history today lives in fragments: batch records sit in manufacturing systems, while shipping routes, temperature exposure and dwell times sit in separate supply-chain systems. When a quality deviation appears downstream, teams must reconstruct that history manually before deciding whether to release, restrict or reject product. The delay costs product, time and confidence in supply.
What does the acquisition change technically?
ParkourSC already had access options on the manufacturing side. It could have built its own connectors to batch-record systems, according to president and CEO Mahesh Veerina, "but it's not about the data itself." Quartic, he explains, "consumes this data, contextualizes it around batches and campaigns, and creates intelligence about the key quality attributes" — the measurable properties, such as purity or potency, that determine whether a batch meets specification. Those attributes feed the downstream decisions ParkourSC's existing platform was built to support.
The timing tracks a structural shift in the industry. Sponsors are moving more of their portfolios into biologics, and production now spreads across a wider mix of internal plants and contract sites. "Supply chain systems, both clinical and commercial, need to become more dynamic in their decision intelligence," Veerina said.
How would a cold-chain excursion play out?
Consider a temperature breach during shipping. Under current practice, a quality team typically judges a cold-chain excursion by what happened on the final leg of a shipment. Linking manufacturing and distribution data, Veerina said, "turns a temperature excursion from an isolated event into a decision made with the batch's full story."
Teams could see the cumulative time a batch has spent in and out of refrigeration from the plant onward, rather than from the warehouse dock forward. The platform would also predict the remaining stability margin — the window in which the product stays within specification — "as excursions occur, so teams know early how much margin a batch has left." Veerina argues the resulting release, restrict or reject decisions become "faster and better justified."
Where do the yield claims come from?
The upstream case rests on model reuse. Quartic applies shared models across research, clinical and commercial manufacturing, so the multivariate models (statistical models tracking several process variables at once) built for clinical batches "act as the starting point, rather than developing models from scratch," Veerina said. That shortens scale-up and process qualification.
The reported 15 to 20% yield gain comes from models that let operators "run the process close to the ideal-yield batch, repeatably," he said. These figures are vendor-reported; the source material does not specify the number of batches, sites or products behind them, and buyers weighing the platform should ask for exactly that evidence.
Who decides in a GxP environment?
The regulatory question is the harder one. In a GxP setting — one governed by good-practice quality regulations — Veerina draws a firm line between recommendation and authority. "AI recommends, and a qualified person decides. AI never makes the GxP decision," he said.
The platform relies on interpretable statistical methods, described as "never black-box models or LLMs," keeps every recommendation within validated ranges, and attaches a confidence interval plus the factors behind it. A human approves each decision with an e-signature, and an audit trail links the underlying data, the recommendation and the final call.
Neither company disclosed the acquisition price. The test ahead is whether quality organizations, which move cautiously by regulation and by temperament, accept combined manufacturing-and-distribution intelligence as a basis for batch disposition decisions.
via Genetic Engineering & Biotechnology News (Source)
Filed under
- ai-in-manufacturing
- life-sciences
- biologics
- supply-chain-analytics
- gxp-compliance
More from Rebecca Stone
Show full bio
Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.
275 articles
References
- Biologics Fill-Finish Tech Transfer Draws Operational Scrutiny
- Tech Transfer Timelines: CDMO Panel Targets 8 Months Cut to 8 Weeks
- Technology Transfer: The Quiet Bottleneck in Pharma Value
- Just-Evotec Opens CHO Media Platform to Market After 70-Project Run
- Sterile Injectables to Hit $984B by 2031, Raising Transfer Stakes